Last $36.09 USD
Change Today -0.05 / -0.14%
Volume 231.5K
RHHBY On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 12:26 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHHBY) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $38.71
52 Week Low
06/24/13 - $28.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

roche holdings ltd-spons adr (RHHBY) Related Bloomberg News

View More Bloomberg News

roche holdings ltd-spons adr (RHHBY) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holdings ltd-spons adr (RHHBY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holdings ltd-spons adr (RHHBY) Key Developments

Roche Enters into Oncology Research Collaboration with Oryzon Genomics

Roche has entered into a global research, development, and commercialisation collaboration with Oryzon Genomics for the latter's inhibitors of lysine specific demethylase-1 (LSD1/KDM1A). As per the agreement, Roche gains the responsibility for developing and commercialising Oryzon's lead agent, ORY-1001, which is in the process of undergoing Phase I/IIA development for acute myeloid leukaemia (AML), as well as/or its backup compounds. Roche will also be licensing two patent families created by Oryzon as part of its research in LSD1, with the Roche also having the option to include other programmes. Furthermore, the companies will undertake collaborative research programme that will initially span two years in order to 'better understand the potential of LSD1 inhibitors in oncology and haematology. The collaboration will be between Oryzon and Roche's New York-based Translational and Clinical Research Centre (TCRC). In turn, Oryzon will receive upfront and near-term milestone payments amounting to USD 21 million. It would also be eligible for over USD 500 million-worth of development, commercialisation, and sales milestone payments, and up to double-digit royalties on sales.

Roche Holding AG to Report Q1, 2014 Sales/Trading Statement Results on Apr 15, 2014

Roche Holding AG announced that they will report Q1, 2014 sales/trading statement results on Apr 15, 2014

Roche Holding AG Presents at Boston Biotech BD Boston Conference, Mar-26-2014 01:00 PM

Roche Holding AG Presents at Boston Biotech BD Boston Conference, Mar-26-2014 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Bob Silverman.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHBY:US $36.09 USD -0.05

RHHBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.03 USD +0.21
Merck & Co Inc $56.09 USD +0.04
Novartis AG SFr.74.35 CHF +0.80
Pfizer Inc $30.03 USD +0.135
Sanofi €74.77 EUR +0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation RHHBY Industry Range
Price/Earnings 19.9x
Price/Sales 4.5x
Price/Book 11.3x
Price/Cash Flow 16.2x
TEV/Sales 3.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at